Crescent Biopharma (CBIO) Reiterated at Buy by Stifel on Comprehensive Pipeline Update

October 16, 2026 7:08 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $28.00 price target on Crescent Biopharma Inc (NASDAQ: CBIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found